1-17 of 17
Justin F. Gainor
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non–Small Cell Lung Cancer

Miguel Lopez de Rodas, Yvonne Wang, Gang Peng, Jianlei Gu, Mari Mino-Kenudson, Jonathan W. Riess, Vamsidhar Velcheti, Matthew Hellmann, Justin F. Gainor, Hongyu Zhao, Kurt A. Schalper
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (5): 998–1008.
https://doi.org/10.1158/1078-0432.CCR-23-2457
Published: 01 March 2024
View article titled, Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non–Small Cell Lung Cancer
Open the PDF for Objective Analysis and Clinical Significance of the Spatial Tumor-Infiltrating Lymphocyte Patterns in Non–Small Cell Lung Cancer in another window
Journal Articles

Facts and Hopes: Immunocytokines for Cancer Immunotherapy

Aliyah Pabani, Justin F. Gainor
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (19): 3841–3849.
https://doi.org/10.1158/1078-0432.CCR-22-1837
Published: 02 October 2023
View article titled, Facts and Hopes: Immunocytokines for Cancer Immunotherapy
Open the PDF for Facts and Hopes: Immunocytokines for Cancer Immunotherapy in another window
Journal Articles

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T. Gibney, Howard A. Burris, Scott S. Tykodi, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jimenez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3695–3708.
https://doi.org/10.1158/1078-0432.CCR-21-4256
Published: 01 September 2022
View article titled, First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Open the PDF for First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response in another window
Includes: Supplementary data
Journal Articles

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

Joshua K. Sabari, Vamsidhar Velcheti, Kazuhide Shimizu, Matthew R. Strickland, Rebecca S. Heist, Mohini Singh, Naema Nayyar, Anita Giobbie-Hurder, Subba R. Digumarthy, Justin F. Gainor, Anant P. Rajan, Edwin Nieblas-Bedolla, Aaron C. Burns, Jill Hallin, Peter Olson, James G. Christensen, Sylvia C. Kurz, Priscilla K. Brastianos, Hiroaki Wakimoto
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3318–3328.
https://doi.org/10.1158/1078-0432.CCR-22-0383
Published: 02 August 2022
View article titled, Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS<sup>G12C</sup>-Mutant Non–Small Cell Lung Cancer
Open the PDF for Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS<sup>G12C</sup>-Mutant Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study

Melissa Johnson, Arkadiusz Z. Dudek, Ammar Sukari, Justin Call, Paul R. Kunk, Karl Lewis, Justin F. Gainor, John Sarantopoulos, Patrice Lee, Adele Golden, Allison Harney, S. Michael Rothenberg, Yuanyuan Zhang, Jonathan W. Goldman
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2517–2526.
https://doi.org/10.1158/1078-0432.CCR-21-3009
Published: 13 June 2022
View article titled, ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
Open the PDF for ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study in another window
Includes: Supplementary data
Journal Articles

Searching for Synergy: Chemotherapy and Checkpoint Inhibitors

Diane Tseng, Justin F. Gainor
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2206–2208.
https://doi.org/10.1158/1078-0432.CCR-22-0335
Published: 01 June 2022
View article titled, Searching for Synergy: Chemotherapy and Checkpoint Inhibitors
Open the PDF for Searching for Synergy: Chemotherapy and Checkpoint Inhibitors in another window
Journal Articles

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial

Vivek Subbiah, Justin F. Gainor, Geoffrey R. Oxnard, Daniel S.W. Tan, Dwight H. Owen, Byoung Chul Cho, Herbert H. Loong, Caroline E. McCoach, Jared Weiss, Yu Jung Kim, Lyudmila Bazhenova, Keunchil Park, Haruko Daga, Benjamin Besse, Oliver Gautschi, Christian Rolfo, Edward Y. Zhu, Jennifer F. Kherani, Xin Huang, Suhyun Kang, Alexander Drilon
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4160–4167.
https://doi.org/10.1158/1078-0432.CCR-21-0800
Published: 01 August 2021
View article titled, Intracranial Efficacy of Selpercatinib in <em>RET</em> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
Open the PDF for Intracranial Efficacy of Selpercatinib in <em>RET</em> Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial in another window
Includes: Supplementary data
Journal Articles

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer

Jessica J. Lin, Noura J. Choudhury, Satoshi Yoda, Viola W. Zhu, Ted W. Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Charlotte Lee, Andrew Do, Jennifer Peterson, Kylie Prutisto-Chang, Wafa Malik, Harper G. Hubbeling, Adam Langenbucher, Adam J. Schoenfeld, Christina J. Falcon, Jennifer S. Temel, Lecia V. Sequist, Beow Y. Yeap, Jochen K. Lennerz, Alice T. Shaw, Michael S. Lawrence, Sai-Hong Ignatius Ou, Aaron N. Hata, Alexander Drilon, Justin F. Gainor
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (10): 2899–2909.
https://doi.org/10.1158/1078-0432.CCR-21-0032
Published: 15 May 2021
View article titled, Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <em>ROS1</em> Fusion–Positive Lung Cancer
Open the PDF for Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <em>ROS1</em> Fusion–Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Progresses Toward Precision Medicine in RET-altered Solid Tumors

Carmen Belli, Santosh Anand, Justin F. Gainor, Frederique Penault-Llorca, Vivek Subbiah, Alexander Drilon, Fabrice Andrè, Giuseppe Curigliano
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6102–6111.
https://doi.org/10.1158/1078-0432.CCR-20-1587
Published: 01 December 2020
View article titled, Progresses Toward Precision Medicine in <em>RET</em>-altered Solid Tumors
Open the PDF for Progresses Toward Precision Medicine in <em>RET</em>-altered Solid Tumors in another window
Journal Articles

MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer

Ibiayi Dagogo-Jack, Satoshi Yoda, Jochen K. Lennerz, Adam Langenbucher, Jessica J. Lin, Marguerite M. Rooney, Kylie Prutisto-Chang, Audris Oh, Nathaniel A. Adams, Beow Y. Yeap, Emily Chin, Andrew Do, Hetal D. Marble, Sara E. Stevens, Subba R. Digumarthy, Ashish Saxena, Rebecca J. Nagy, Cyril H. Benes, Christopher G. Azzoli, Michael S. Lawrence, Justin F. Gainor, Alice T. Shaw, Aaron N. Hata
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (11): 2535–2545.
https://doi.org/10.1158/1078-0432.CCR-19-3906
Published: 01 June 2020
View article titled, MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Open the PDF for MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

Ibiayi Dagogo-Jack, Marguerite Rooney, Jessica J. Lin, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (22): 6662–6670.
https://doi.org/10.1158/1078-0432.CCR-19-1436
Published: 15 November 2019
View article titled, Treatment with Next-Generation ALK Inhibitors Fuels Plasma <em>ALK</em> Mutation Diversity
Open the PDF for Treatment with Next-Generation ALK Inhibitors Fuels Plasma <em>ALK</em> Mutation Diversity in another window
Includes: Supplementary data
Journal Articles

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis

Ila Datar, Miguel F. Sanmamed, Jun Wang, Brian S. Henick, Jungmin Choi, Ti Badri, Weilai Dong, Nikita Mani, Maria Toki, Luis D. Mejías, Maria D. Lozano, Jose Luis Perez-Gracia, Vamsidhar Velcheti, Matthew D. Hellmann, Justin F. Gainor, Kristen McEachern, David Jenkins, Konstantinos Syrigos, Katerina Politi, Scott Gettinger, David L. Rimm, Roy S. Herbst, Ignacio Melero, Lieping Chen, Kurt A. Schalper
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4663–4673.
https://doi.org/10.1158/1078-0432.CCR-18-4142
Published: 01 August 2019
View article titled, Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
Open the PDF for Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis in another window
Includes: Supplementary data
Journal Articles

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Justin F. Gainor, Alice T. Shaw, Lecia V. Sequist, Xiujun Fu, Christopher G. Azzoli, Zofia Piotrowska, Tiffany G. Huynh, Ling Zhao, Linnea Fulton, Katherine R. Schultz, Emily Howe, Anna F. Farago, Ryan J. Sullivan, James R. Stone, Subba Digumarthy, Teresa Moran, Aaron N. Hata, Yukako Yagi, Beow Y. Yeap, Jeffrey A. Engelman, Mari Mino-Kenudson
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (18): 4585–4593.
https://doi.org/10.1158/1078-0432.CCR-15-3101
Published: 15 September 2016
View article titled, <em>EGFR</em> Mutations and <em>ALK</em> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
Open the PDF for <em>EGFR</em> Mutations and <em>ALK</em> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis in another window
Includes: Supplementary data
Journal Articles

Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Justin F. Gainor, Daniel S.W. Tan, Tomasso De Pas, Benjamin J. Solomon, Aziah Ahmad, Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (12): 2745–2752.
https://doi.org/10.1158/1078-0432.CCR-14-3009
Published: 14 June 2015
View article titled, Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib
Open the PDF for Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib in another window
Includes: Supplementary data
Journal Articles

Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib

Ryohei Katayama, Luc Friboulet, Sumie Koike, Elizabeth L. Lockerman, Tahsin M. Khan, Justin F. Gainor, A. John Iafrate, Kengo Takeuchi, Makoto Taiji, Yasushi Okuno, Naoya Fujita, Jeffrey A. Engelman, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5686–5696.
https://doi.org/10.1158/1078-0432.CCR-14-1511
Published: 13 November 2014
View article titled, Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Open the PDF for Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib in another window
Includes: Supplementary data
Journal Articles

Pharmacodynamic Biomarkers: Falling Short of the Mark?

Justin F. Gainor, Dan L. Longo, Bruce A. Chabner
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (10): 2587–2594.
https://doi.org/10.1158/1078-0432.CCR-13-3132
Published: 14 May 2014
View article titled, Pharmacodynamic Biomarkers: Falling Short of the Mark?
Open the PDF for Pharmacodynamic Biomarkers: Falling Short of the Mark? in another window
Journal Articles

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

Justin F. Gainor, Anna M. Varghese, Sai-Hong Ignatius Ou, Sheheryar Kabraji, Mark M. Awad, Ryohei Katayama, Amanda Pawlak, Mari Mino-Kenudson, Beow Y. Yeap, Gregory J. Riely, A. John Iafrate, Maria E. Arcila, Marc Ladanyi, Jeffrey A. Engelman, Dora Dias-Santagata, Alice T. Shaw
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (15): 4273–4281.
https://doi.org/10.1158/1078-0432.CCR-13-0318
Published: 31 July 2013
View article titled, <em>ALK</em> Rearrangements Are Mutually Exclusive with Mutations in <em>EGFR</em> or <em>KRAS</em>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
Open the PDF for <em>ALK</em> Rearrangements Are Mutually Exclusive with Mutations in <em>EGFR</em> or <em>KRAS</em>: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer in another window